CONFIRMED PLENARY SPEAKERS
DR. JOY WU
Joy Wu is Chief of the Division of Endocrinology and Vice Chair of Basic and Translational Science in the Department of Medicine at Stanford University School of Medicine. Dr. Wu directs a translational research program that focuses on skeletal development, stem cell therapies for bone, and breast cancer bone metastases, and has an active clinical practice focused on osteoporosis and bone health in cancer. She has served on clinical guideline committees for the Endocrine Society, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. Wu earned her M.D. and Ph.D. degrees at Duke University and completed her clinical training in endocrinology at Harvard Medical School before joining the Stanford faculty. She has previously served on the Board of Directors of the Endocrine Society and is currently a member of the Council of the American Society for Bone and Mineral Research.
PROF. RICHARD ROSS
Trained in medicine at The Royal London Hospital (1974-1979) and in Endocrinology at St Bartholomew’s Hospital, London (1983-1988). Appointed to Sheffield University in 1995 and is Professor of Endocrinology, past Head of Section and currently theme lead for Diabetes, Endocrinology and Metabolism. Retired from clinical practice in 2021. Richard’s research and clinical interests are in pituitary and adrenal disease, transition endocrinology and the late effects of cancer. Richard has a particular interest in commercial research and was founding Director of two university spin-out companies; Asterion Ltd, developing long-acting hormone analogues and Diurnal Ltd, developing circadian endocrine therapies. Diurnal launched it’s first product, Alkindi®, in 2018 in the European Union and subsequently USA. Alkindi® is the first preparation of hydrocortisone specifically designed for use in children suffering from adrenal insufficiency. Diurnal’s second product, Efmody®, that replaces the circadian rhythm of cortisol, was approved by the European Commission in May 2021 and MHRA in July 2021. Richard was Chief Scientific Officer and Director on the Board of Diurnal Group Plc (2004-2022); overseeing its flotation in 2015 on the London Stock market (AIM) prior to its purchase by Neurocrine Biosciences in 2022. Served on the editorial boards of: Clinical Endocrinology (1996-2000), Growth & Growth Factors (1986-2006), Hormones (2004-2018), and J Clin Endocrinol Metab (2010-2014). Council member for the Society of Endocrinology (1999-2002), Editor Endocrinologist (2001-2004), Chair of CaHASE (2002-2015), member of the Bioscientifica Board (2006-2010), Society for Endocrinology Public Engagement Committee (2008-2011) and Nominations Committee (2010-2012). Executive Committee of the European Society of Endocrinology (2011-2015), Treasurer of the European Society of Endocrinology (2013-2015), The Growth Hormone Research Society Council (2011-2018), and The Pituitary Society Board of Directors (2019-). Received The Endocrine Societies “Outstanding Innovation Award” in 2021 and awarded the Clinical Endocrinology Trust Award at ECE 2023. President Elect Pituitary Society (2023).